Blog | BioInformant

The Making of a Stem Cell Super-Ecosystem with Bernard Siegel

January 17, 2018 By Cade Hildreth, Founder & President Leave a Comment

I am honored to share this interview with Bernard Siegel, Executive Director of the Regenerative Medicine Foundation (RMF), a global network of stakeholders that fosters collaboration across the industry. Bernard is also the Founder and Chair of the World Stem Cell Summit (WSCS), my favorite stem cell industry event of the year, because it attracts a global super-ecosystem of stem cell industry stakeholders.

In this interview, we explore his background, changes within the regenerative medicine sector, the importance of industry collaboration, and future directions for stem cell medicine. [Read more…]

Exosome Manufacturing: $2.18M Grant Awarded to VivaZome Therapeutics

January 13, 2018 By Cade Hildreth, Founder & President Leave a Comment

$2.18m grant awarded to VivaZome Therapeutics for Exosome Therapy; Grant awarded in collaboration with La Trobe University and SeerPharma

18 December 2017, Geelong – Melbourne, Australia: Australian biotech company VivaZome Therapeutics is pleased to announce that it has been awarded an Australian Government CRC-P grant of $2.18m in support of the project “Enabling Exosome Therapy: Developing an Advanced Manufacturing Process”, with the funds provided under the Advanced Manufacturing Scheme.

The Hon Craig Laundy MP (Assistant Minister for Industry, Innovation and Science) oversees the Cooperative Research Centre Projects (CRC-P) Grants Scheme which supports the development of innovative Australian companies and sectors.

Joining VivaZome in the CRC-P are La Trobe University and SeerPharma Pty Ltd, each of which bring high-level scientific and operational skills to the 3 –year project. VivaZome will also engage with the CSIRO to provide expertise in industrial–scale manufacturing. [Read more…]

ArunA Biomedical Launches Exosome Biologics to Treat CNS and Neurodegenerative Disorders

January 11, 2018 By Cade Hildreth, Founder & President Leave a Comment

Company rapidly moving toward clinical development of cell-free biologic therapy as study published in Translational Stroke Research demonstrates human neural exosomes improve tissue and functional recovery in pre-clinical model

January 03, 2018 08:00AM, ATHENS, Ga. — ArunA Biomedical announces the official launch of a new class of cell-free exosome biologics to treat central nervous system and neurodegenerative disorders. With an initial focus on an exosome therapeutic for stroke, the company published results of a study today in Translational Stroke Research that found extracellular vesicles (EVs) derived from human neural stem cells improved tissue and functional recovery in murine thromboembolic stroke models.

The study was led by Dr. Steven Stice, a Georgia Research Alliance Eminent Scholar endowed chair, Professor and Director of the Regenerative Bioscience Center at The University of Georgia and who serves as Co-Founder, Chief Executive and Chief Scientific Officer for ArunA Biomedical. The study was conducted in collaboration with Dr. Nasrul Hoda at Augusta University. [Read more…]

GenCure Opens BioManufacturing Center for cGMP Production of Human MSCs

January 10, 2018 By Cade Hildreth, Founder & President Leave a Comment

Biologics development and manufacturing organization supports transfer of laboratory research from preclinical evaluation through clinical trials and commercialization

Veritas Genetics Launches Collaboration with Mayo Clinic to Integrate Whole Genome Sequencing into Clinical Care

January 8, 2018 By Cade Hildreth, Founder & President Leave a Comment

Goal is to empower physicians and patients through making whole genome sequencing broadly available

BOSTON, Jan. 8, 2018— Veritas Genetics, The Genome Company, and Mayo Clinic are entering into an agreement to make whole genome sequencing broadly available to healthy individuals.

As part of this collaboration:

The team at Mayo Clinic’s Center for Individualized Medicine will provide medical and clinical expertise to the Veritas team.
Veritas will integrate Mayo Clinic’s know-how into its flagship product myGenome.
Patients who qualify for a Mayo Clinic research study of healthy adults will be offered Veritas myGenome screening test for whole genome sequencing.
Mayo Clinic will become a shareholder of Veritas.

“The Center for Individualized Medicine at Mayo Clinic is the gold standard in personalized medicine and we are proud and honored to collaborate with such a professional and dedicated team. This is a great step to further realize the promise of the human genome,” expressed Mirza Cifric, Founder, CEO Veritas Genetics. [Read more…]